Publications by authors named "Susan VanMeter"

Claim this Profile
P
Pyrimidine Nucleos(t)ide Therapy in Patients With Thymidine Kinase 2 Deficiency: A Multicenter Retrospective Chart Review Study.
Cristina Domínguez-González, Carl Chiang, Anny-Odile Colson, Irene Rebollo Mesa, Ester Baixauli, Susan VanMeter

Neurology· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of a 1:1 Mixture of Doxecitine and Doxribtimine: Open-label Phase 1 Single Ascending Dose and Food Effect Studies in Healthy Adults.
Aravind Mittur, Susan A VanMeter, Elmar Orujov, Paul Glidden

Clin Ther· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of Hepatic Encephalopathy from a Commercial Medical Claims Database in the United States.
Aniruddha Potnis, Susan VanMeter, Jan Stange

Int J Hepatol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
Amit Bar-Or, Richard A Grove, Daren J Austin, Jerry M Tolson, Susan A VanMeter

Neurology· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A fixed-dose, dose-response study of ropinirole prolonged release in early stage Parkinson's disease.
Theresa A Zesiewicz, Stephen Chriscoe, Theresa Jimenez, James Upward, Susan VanMeter

Neurodegener Dis Manag· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, fixed-dose, dose-response study of ropinirole prolonged release in advanced Parkinson's disease.
Theresa A Zesiewicz, Stephen Chriscoe, Theresa Jimenez, James Upward, Maria Davy, Susan VanMeter

Neurodegener Dis Manag· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term, open-label, safety study of once-daily ropinirole extended/prolonged release in early and advanced Parkinson's disease.
Clare W Makumi, Afsaneh Asgharian, Jeffrey Ellis, Soraya Shaikh, Teri Jimenez, Susan VanMeter

Int J Neurosci· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges and opportunities in designing clinical trials for neuromyelitis optica.
Brian G Weinshenker, Gerard Barron, Jacinta M Behne, Jeffery L Bennett, Peter S Chin, Susan VanMeter

Neurology· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose response of Gabapentin Enacarbil versus placebo in subjects with moderate-to-severe primary restless legs syndrome: an integrated analysis of three 12-week studies.
Susan A VanMeter, Sarah T Kavanagh, Samantha Warren, Ronald W Barrett

CNS Drugs· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.
James W Jefferson, A John Rush, J Craig Nelson, Susan A VanMeter, Alok Krishen

J Clin Psychiatry· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials.
Michael E Thase, Barbara R Haight, Nathalie Richard, Carol B Rockett, Melinda Mitton, Susan VanMeter

J Clin Psychiatry· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis